Shaping the future of children’s healthcare together
17 June 2026
Rise in respiratory infections and measles outbreak: important infection prevention measures at the Montreal Children’s Hospital.
Read more
4 October 2024
As of November 1, 2024, a new medication called nirsevimab will be available in Quebec to prevent respiratory syncytial virus (RSV).
RSV is a common, highly contagious respiratory virus, infecting nearly all children by two years of age.
It is the most common cause of bronchiolitis and pneumonia in children less than one year of age.
A Quebec-based study found RSV was the most common virus (63.6 per cent) in children hospitalized for acute respiratory infection, with higher severity in children born prematurely and babies under six months of age (Papenburg et al, 2012).
Nirsevimab will be available at CLSCs and local points of service for:
How is it given?
Nirsevimab is administered at the start/during RSV season as an intramuscular injection, usually in the thigh muscle.
Where will it be given?
Don’t hesitate to book an appointment for your child!
Shaping the future of children’s healthcare together
17 June 2026
Lice… Lice… Lice… All there is to know about head lice
30 April 2026